HATTR-PN

Clinical trials for HATTR-PN explained in plain language.

Never miss a new study

Get alerted when new HATTR-PN trials appear

Sign up with your email to follow new studies for HATTR-PN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New shot every 6 months could slow rare nerve disease

Disease control Recruiting now

This Phase 3 trial tests a new drug called nucresiran in 125 people with a rare inherited condition that damages nerves (hATTR-PN). The drug is given as a shot under the skin every 6 months and aims to slow nerve damage and improve quality of life. Researchers will compare it to …

Matched conditions: HATTR-PN

Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

HATTR-PN

Get alerted when new HATTR-PN trials appear

New shot every 6 months could slow rare nerve disease